Last reviewed · How we verify
Corticosteroid: Meprednisone
Glucocorticoid receptor agonist
Glucocorticoid receptor agonist Used for Treatment of various cancers.
At a glance
| Generic name | Corticosteroid: Meprednisone |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | Glucocorticoid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Meprednisone acts as a synthetic glucocorticoid receptor agonist, mimicking the effects of cortisol in the body.
Approved indications
- Treatment of various cancers
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Headache
- Fatigue
Key clinical trials
- Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Corticosteroid: Meprednisone CI brief — competitive landscape report
- Corticosteroid: Meprednisone updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI